Pre-clinical studies have shown that mesenchymal-like breast cancer cell lines are sensitive to the cytotoxic effects of TRAIL whereas epithelial-like lines are TRAIL-resistant [19]. This evidence concerns the gene TNFSF10 and breast carcinoma.